- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1869-6961
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Population Pharmacokinetics of Semaglutide for Type 2 Diabetes ; day:20 ; month:2 ; year:2019 ; pages:1-14
Diabetes therapy ; (20.2.2019), 1-14
- Urheber
-
Overgaard, Rune V.
Delff, Philip H.
Petri, Kristin C. C.
Anderson, Thomas W.
Flint, Anne
Ingwersen, Steen H.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s13300-019-0581-y
- URN
-
urn:nbn:de:101:1-2019032014372910552173
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:57 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Overgaard, Rune V.
- Delff, Philip H.
- Petri, Kristin C. C.
- Anderson, Thomas W.
- Flint, Anne
- Ingwersen, Steen H.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis
Effect of upper gastrointestinal disease on the pharmacokinetics of oral semaglutide in subjects with type 2 diabetes
Response to semaglutide of non-drinker subjects with type 2 diabetes
Semaglutide
Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials
Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment
Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes
Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics
Real-world use of once-weekly semaglutide in type 2 diabetes: results from SURE Germany
A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes
Population Pharmacokinetics and Exposure–Response (Efficacy and Safety/Tolerability) of Empagliflozin in Patients with Type 2 Diabetes
Real-World Treatment Patterns Among Patients with Type 2 Diabetes Mellitus Initiating Treatment with Oral Semaglutide
Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis
Effect of upper gastrointestinal disease on the pharmacokinetics of oral semaglutide in subjects with type 2 diabetes
Response to semaglutide of non-drinker subjects with type 2 diabetes
Semaglutide
Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials
Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment
Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes
Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics
Real-world use of once-weekly semaglutide in type 2 diabetes: results from SURE Germany
A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes
Population Pharmacokinetics and Exposure–Response (Efficacy and Safety/Tolerability) of Empagliflozin in Patients with Type 2 Diabetes
Real-World Treatment Patterns Among Patients with Type 2 Diabetes Mellitus Initiating Treatment with Oral Semaglutide
Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis
Effect of upper gastrointestinal disease on the pharmacokinetics of oral semaglutide in subjects with type 2 diabetes
Response to semaglutide of non-drinker subjects with type 2 diabetes
Semaglutide
Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials
Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment
Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes
Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics
Real-world use of once-weekly semaglutide in type 2 diabetes: results from SURE Germany
A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes
Population Pharmacokinetics and Exposure–Response (Efficacy and Safety/Tolerability) of Empagliflozin in Patients with Type 2 Diabetes